While MYC amplification was an acquired molecular event (included in the NGS panel used for the initial and metastatic tumor), it is not clear whether HSP90AB1, VEGFA, or GRIN2A were present at the time of initial diagnosis. The gene discussed is GRIN2A; the disease is metastatic neoplasm.